Epify develops epigenetic biomarkers which control gene activity and are implicated in a wide range of cancers, driving and influencing the development of the disease.
Using these biomarkers, Epify aims to drive earlier detection and more accurate diagnosis, facilitating personalized oncology and better outcomes for cancer patients.
Using these biomarkers, Epify aims to drive earlier detection and more accurate diagnosis, facilitating personalized oncology and better outcomes for cancer patients.
Location: Netherlands, Limburg, Maastricht
Employees: 1-10
Total raised: $564.63K
Founded date: 2019
Investors 1
| Date | Name | Website |
| - | Novalis Bi... | noval.is |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 26.09.2019 | Seed | $564.63K | - |
Mentions in press and media 2
| Date | Title | Description |
| 26.08.2023 | Blooming Innovation: 15 Cutting-Edge Biotechnology Startups in The Netherlands | Table of Contents show 1 Introduction 2 New Amsterdam Pharma: Revolutionizing Cardio-Metabolic Therapies 3 The Protein Brewery: Crafting Sustainable, Animal-Free Proteins 4 Epify: Transforming Healthcare with Collaborative Innovation 5... |
| - | Epify raises 500,000 Euro in seeding round |